Purpose Cancer therapies including trastuzumab and anthracyclines are cardiotoxic and
cause cardiac dysfunction. To prevent cardiotoxicity, pharmacological agents used in heart�…

Cardiac toxicity is one of the most important long-term toxicities experienced by cancer
survivors so that survival rate due to anticancer therapy may be negatively affected due to�…

Cancer therapy‐related cardiac dysfunction (CTRCD) is a complication of selected cancer
therapy agents associated with decline in left ventricular ejection fraction (LVEF)�…

Background Cardiotoxicity is a well-known adverse effect of anthracyclines and
trastuzumab. The roles of statins, beta blockers (BBs), and ACEI/ARBs in the context of�…

Anthracycline (doxorubicin) and trastuzumab treatments for cancer patients have been
known to cause cardiotoxicity. The current recommendations for prevention of cardiac�…

Anthracycline (doxorubicin) and trastuzumab treatments for cancer patients have been
known to cause cardiotoxicity. The current recommendations for prevention of cardiac�…

Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)
may attenuate cancer therapy–related cardiac dysfunction (CTRCD). However, results of the�…

e14513 Background: Chemotherapeutic agents, specifically anthracyclines and trastuzumab
are known to cause dose dependent cardiotoxicity ranging from subclinical changes in�…

Aims Conventional cytotoxic chemotherapy is still among the most effective treatment
options for many types of cancer. However, cardiotoxicity, notably the decrease in left�…

Background Although previous clinical randomized controlled trials (RCTs) have tested the
effect of a variety of cardioprotective agents on cancer therapy-induced cardiotoxicity, the�…